Cannabinoids in peripheral neuropathic pain: Resolving mechanistic mismatch through CB2-oriented phenotype stratification.

Abstract excerpt

Peripheral neuropathic pain (PNP) affects approximately 7-10% of the population, yet 40-60% of patients derive inadequate relief from first-line pharmacotherapies. Cannabinoid-based medicines engage the endocannabinoid system and offer a strong biological rationale for analgesia, but randomised trials show only modest, heterogeneous benefits and non-trivial adverse-effect liability. The 2025 Neuropathic Pain...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Analgesics
• Share to Cannabinoids
• Share to PNP gene